1
|
Melé-Ninot G, Curto-Barredo L, Bonfill-Ortí M, Expósito-Serrano V, Munera-Campos M, Figueras Nart I, Riquelme-Mc Loughlin C, Gómez-Armayones S, Spertino J, Serra-Baldrich E. Assessment of potential predictive factors of dupilumab response in patients with moderate-to-severe atopic dermatitis. Australas J Dermatol 2024; 65:153-162. [PMID: 38058123 DOI: 10.1111/ajd.14196] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2023] [Revised: 11/01/2023] [Accepted: 11/21/2023] [Indexed: 12/08/2023]
Abstract
BACKGROUND Dupilumab has shown to be an effective and safe treatment for patients with moderate-to-severe atopic dermatitis (AD). OBJECTIVE To evaluate the predictive factors of response (PRF) in patients with moderate-to-severe AD treated with dupilumab. METHODS Observational, retrospective and multicentre study conducted on adult patients diagnosed with moderate-to-severe AD treated with dupilumab, with a post-treatment follow-up of at least 16 weeks. The primary endpoints were EASI-75 and the IGA scale at week 52. RESULTS A total of 198 patients were included in the analysis. Mean age was 38 ± 15.1 years and 116 (58.6%) were men. The most prevalent AD-predominant phenotypes were flexural eczema (45.3%), head-and-neck eczema (18.2%) and erythroderma (17.7%). At week 52, 140 (86.4%) patients achieved EASI-75 and 119 (93.0%) achieved an improvement in ≥2 points from baseline in IGA score. Women were 3.6 times more likely to achieve EASI-75 response than men (Odds ratio: 3.58; p = 0.020). While increased body mass index significantly reduced the probability of obtaining an improvement of ≥2 points in the IGA scale at week 52 (odds ratio: 0.88; p = 0.049). CONCLUSIONS Dupilumab was an effective treatment in patients with moderate-to-severe AD. Additionally, sex and body mass index were significantly associated with achieving EASI-75 and an improvement of ≥2 points in the IGA scale, respectively, at week 52.
Collapse
Affiliation(s)
- Gemma Melé-Ninot
- Dermatology Department, Hospital Universitari Sagrat Cor, Grupo Quirónsalud, Barcelona, Spain
| | - Laia Curto-Barredo
- Dermatology Department, Hospital del Mar-Institut Mar d'Investigacions Mèdiques, Barcelona, Spain
| | | | | | - Mónica Munera-Campos
- Dermatology Department, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, Germans Trias i Pujol Research Institute (IGTP), Barcelona, Spain
| | - Ignasi Figueras Nart
- Dermatology Department, Hospital del Mar-Institut Mar d'Investigacions Mèdiques, Barcelona, Spain
| | | | | | - Jorge Spertino
- Dermatology Department, Hospital de la Santa Creu i Sant Pau Hospital, Barcelona, Spain
| | - Esther Serra-Baldrich
- Dermatology Department, Hospital de la Santa Creu i Sant Pau Hospital, Barcelona, Spain
| |
Collapse
|
2
|
Carmona-Rocha E, Aguado M, Tubau C, Sánchez S, Mozos A, Sullivan I, Spertino J. Epidermolysis bullosa acquisita ausgelöst durch Atezolizumab. J Dtsch Dermatol Ges 2023; 21:1407-1409. [PMID: 37946658 DOI: 10.1111/ddg.15203_g] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2023] [Accepted: 07/09/2023] [Indexed: 11/12/2023]
Affiliation(s)
- Elena Carmona-Rocha
- Dermatology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | - María Aguado
- Oncology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | - Carla Tubau
- Dermatology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | - Sofía Sánchez
- Oncology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | - Anna Mozos
- Anatomical Pathology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | - Ivana Sullivan
- Oncology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | - Jorge Spertino
- Dermatology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| |
Collapse
|
3
|
Carmona-Rocha E, Aguado M, Tubau C, Sánchez S, Mozos A, Sullivan I, Spertino J. Epidermolysis bullosa acquisita induced by atezolizumab. J Dtsch Dermatol Ges 2023; 21:1407-1409. [PMID: 37658659 DOI: 10.1111/ddg.15203] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2023] [Accepted: 07/09/2023] [Indexed: 09/03/2023]
Affiliation(s)
- Elena Carmona-Rocha
- Dermatology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | - María Aguado
- Oncology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | - Carla Tubau
- Dermatology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | - Sofía Sánchez
- Oncology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | - Anna Mozos
- Anatomical Pathology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | - Ivana Sullivan
- Oncology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | - Jorge Spertino
- Dermatology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| |
Collapse
|
4
|
Rusiñol L, Carmona-Rocha E, Spertino J. Bullous eruption in a pluripathological patient. Int J Dermatol 2023; 62:e312-e313. [PMID: 36683133 DOI: 10.1111/ijd.16590] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/18/2022] [Revised: 12/04/2022] [Accepted: 01/05/2023] [Indexed: 01/24/2023]
Affiliation(s)
- Lluís Rusiñol
- Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona
| | - Elena Carmona-Rocha
- Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona
| | - Jorge Spertino
- Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona
| |
Collapse
|
5
|
Melé-Ninot G, Serra-Baldrich E, Curto-Barredo L, Figueras-Nart I, Spertino J, Expósito-Serrano V, García-Navarro X, Guilabert A, Bielsa-Marsol I, Giménez-Arnau AM. Definition of Recurrent Chronic Spontaneous Urticaria. Acta Derm Venereol 2020; 100:adv00267. [PMID: 32926176 PMCID: PMC9235005 DOI: 10.2340/00015555-3633] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/03/2022] Open
Affiliation(s)
- Gemma Melé-Ninot
- Department of Dermatology, Hospital Universitari Sagrat Cor - Grupo Quirón Salud, ES-08029 Barcelona, Spain. E-mail:
| | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Exposito‐Serrano V, Curto‐Barredo L, Aguilera Peiro P, Gómez Armayones S, Serra‐Baldrich E, Spertino J, Bonfill Ortí M, Figueras Nart I, Melé‐Ninot G, Baliu‐Piqué C, Sala Cunill A, Labrador‐Horrillo M, Guilabert Vidal A, Fernández Chico N, Giménez‐Arnau A. Omalizumab for the treatment of chronic inducible urticaria in 80 patients. Br J Dermatol 2020; 184:167-168. [DOI: 10.1111/bjd.19425] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2020] [Revised: 06/05/2020] [Accepted: 07/26/2020] [Indexed: 12/25/2022]
Affiliation(s)
- V. Exposito‐Serrano
- Departments of Dermatology atDepartment of Dermatology Hospital Universitari Parc Taulí. Sabadell
| | | | | | | | | | - J. Spertino
- Department of Dermatology Hospital de la Santa Creu i Sant Pau
| | | | | | - G. Melé‐Ninot
- Department of Dermatology Hospital Universitari Sagrat Cor
| | - C. Baliu‐Piqué
- Department of Dermatology Hospital d’Igualada‐Consorci Sanitari de l’Anoia
| | - A. Sala Cunill
- Department of Dermatology Allergology Department Hospital Universitari Vall d’Hebron
| | - M. Labrador‐Horrillo
- Department of Dermatology Allergology Department Hospital Universitari Vall d’Hebron
| | | | - N. Fernández Chico
- Departments of Dermatology atDepartment of Dermatology Hospital Universitari Parc Taulí. Sabadell
| | | |
Collapse
|
7
|
Ogueta I, Spertino J, Deza G, Alcantara Luna S, Zaragoza Ninet V, Pujol R, Giménez‐Arnau A. Wells syndrome and chronic spontaneous urticaria: report of four cases successfully treated with omalizumab. J Eur Acad Dermatol Venereol 2019; 33:e388-e391. [DOI: 10.1111/jdv.15683] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Affiliation(s)
- I. Ogueta
- Department of Dermatology Hospital del Mar, IMIM, Universitat Autònoma Barcelona Spain
- Department of Dermatology, Faculty of Medicine Pontificia Universidad Católica de Chile Chile
| | - J. Spertino
- Department of Dermatology Hospital de la Santa Creu i Sant Pau Barcelona Spain
| | - G. Deza
- Department of Dermatology Hospital del Mar, IMIM, Universitat Autònoma Barcelona Spain
| | | | - V. Zaragoza Ninet
- Department of Dermatology Hospital General de Valencia Valencia Spain
| | - R.M. Pujol
- Department of Dermatology Hospital del Mar, IMIM, Universitat Autònoma Barcelona Spain
| | - A.M. Giménez‐Arnau
- Department of Dermatology Hospital del Mar, IMIM, Universitat Autònoma Barcelona Spain
| |
Collapse
|
8
|
Cubiró X, Spertino J, Rozas-Muñoz E, Serra-Baldrich E, Puig L. La efectividad del tratamiento con omalizumab en la vida real es menor en pacientes con urticaria crónica de más de 18 meses de evolución y tratamiento inmunosupresor previo. Actas Dermo-Sifiliográficas 2019; 110:289-296. [DOI: 10.1016/j.ad.2018.09.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2018] [Revised: 08/16/2018] [Accepted: 09/19/2018] [Indexed: 10/28/2022] Open
|
9
|
Cubiró X, Spertino J, Rozas-Muñoz E, Serra-Baldrich E, Puig L. The Effectiveness of Omalizumab Treatment in Real-Life is Lower in Patients with Chronic Urticaria Longer than 18 Months’ Evolution and Prior Immunosuppressive Treatment. Actas Dermo-Sifiliográficas (English Edition) 2019. [DOI: 10.1016/j.adengl.2018.09.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
10
|
Spertino J, Curto Barredo L, Rozas Muñoz E, Figueras Nart I, Serra Baldrich E, Bonfill-Ortí M, Expósito-Serrano V, Guilabert A, Melé Ninot G, Villar Buil M, Garcias Ladaria J, García Navarro X, Vilavella M, Bielsa Marsol I, Aparicio Ortiz G, Baliu Piqué C, Álvarez Abella A, Lamas Domenech N, Mascaró J, Gómez S, Torné Gutiérrez J, Vicente Villa A, Gimenez Arnau A. Algorithm for Treatment of Chronic Spontaneous Urticaria with Omalizumab. Actas Dermo-Sifiliográficas (English Edition) 2018. [DOI: 10.1016/j.adengl.2018.09.011] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
11
|
Spertino J, Curto Barredo L, Rozas Muñoz E, Figueras Nart I, Gimenez Arnau A, Serra Baldrich E, Bonfill-Ortí M, Expósito-Serrano V, Guilabert A, Melé Ninot G, Villar Buil M, Garcias Ladaria J, García Navarro X, Vilavella M, Bielsa Marsol I, Aparicio Ortiz G, Baliu Piqué C, Álvarez Abella A, Lamas Domenech N, Mascaró JM, Gómez S, Torné Gutiérrez JI, Vicente Villa A, Gimenez Arnau A. Algorithm for Treatment of Chronic Spontaneous Urticaria with Omalizumab. Actas Dermosifiliogr (Engl Ed) 2018; 109:771-776. [PMID: 30107875 DOI: 10.1016/j.ad.2018.07.005] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2018] [Revised: 05/20/2018] [Accepted: 07/01/2018] [Indexed: 10/28/2022] Open
Abstract
BACKGROUND AND OBJECTIVE Pivotal trials with omalizumab for treatment of chronic spontaneous urticaria (CSU) are generally run over 12 to 24weeks. However, in clinical practice, many patients need longer treatment. In this article, we present an algorithm for treatment with omalizumab. MATERIAL AND METHODS The consensus document we present is the result of a series of meetings by the CSU working group of "Xarxa d'Urticària Catalana i Balear" (XUrCB) at which data from the recent literature were presented, discussed, compared, and agreed upon. RESULTS Treatment with omalizumab should be initiated at the authorized dose, and is adjusted at 3-monthly intervals according to the Urticaria Activity Score Over 7days, the Urticaria Control Test, or both. CONCLUSIONS The algorithm proposed is designed to provide guidance on how to adjust omalizumab doses, how and when to discontinue the drug, and how to reintroduce it in cases of relapse.
Collapse
Affiliation(s)
- J Spertino
- Servicio de Dermatología, Hospital de la Santa Creu i Sant Pau, Barcelona, España.
| | | | - E Rozas Muñoz
- Servicio de Dermatología, Hospital de la Santa Creu i Sant Pau, Barcelona, España
| | - I Figueras Nart
- Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Barcelona, España
| | | | - E Serra Baldrich
- Servicio de Dermatología, Hospital de la Santa Creu i Sant Pau, Barcelona, España
| | - M Bonfill-Ortí
- Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Barcelona, España
| | | | - A Guilabert
- Hospital General de Granollers, Granollers, Barcelona, España
| | - G Melé Ninot
- Hospital Universitari Sagrat Cor, Barcelona, España
| | - M Villar Buil
- Hospital de Sant Joan Despí Moisès Broggi, Sant Joan Despí, Barcelona, España
| | | | - X García Navarro
- Consorci Sanitari del Garraf, Sant Pere de Ribes, Barcelona, España
| | - M Vilavella
- Consorci Sanitari de Terrassa, Terrassa, Barcelona, España
| | | | | | - C Baliu Piqué
- Consorci Sanitari de l'Anoia, Igualada, Barcelona, España
| | | | | | - J M Mascaró
- Hospital Clínic de Barcelona, Barcelona, España
| | - S Gómez
- Hospital Clínic de Barcelona, Barcelona, España
| | | | - A Vicente Villa
- Hospital Sant Joan de Déu, Esplugues de Llobregat, Barcelona, España
| | | |
Collapse
|
12
|
Curto-Barredo L, Spertino J, Figueras-Nart I, Expósito-Serrano V, Guilabert A, Melé-Ninot G, Cubiró X, Bonfill-Ortí M, Garcias-Ladaria J, Villar M, García-Navarro X, Bielsa-Marsol I, Vilavella M, Aparicio G, Baliu-Piqué C, Álvarez A, Lamas-Domenech N, Duran-Jordà X, Serra-Baldrich E, Giménez-Arnau A. Omalizumab updosing allows disease activity control in patients with refractory chronic spontaneous urticaria. Br J Dermatol 2018; 179:210-212. [DOI: 10.1111/bjd.16379] [Citation(s) in RCA: 33] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Affiliation(s)
- L. Curto-Barredo
- Hospital del Mar Medical Research Institute (IMIM); Universitat Autònoma Barcelona, (UAB) - Dermatology; Barcelona Catalunya Spain
| | - J. Spertino
- Hospital del Mar Medical Research Institute (IMIM); Universitat Autònoma Barcelona, (UAB) - Dermatology; Barcelona Catalunya Spain
| | - I. Figueras-Nart
- Hospital del Mar Medical Research Institute (IMIM); Universitat Autònoma Barcelona, (UAB) - Dermatology; Barcelona Catalunya Spain
| | - V. Expósito-Serrano
- Hospital del Mar Medical Research Institute (IMIM); Universitat Autònoma Barcelona, (UAB) - Dermatology; Barcelona Catalunya Spain
| | - A. Guilabert
- Hospital del Mar Medical Research Institute (IMIM); Universitat Autònoma Barcelona, (UAB) - Dermatology; Barcelona Catalunya Spain
| | - G. Melé-Ninot
- Hospital del Mar Medical Research Institute (IMIM); Universitat Autònoma Barcelona, (UAB) - Dermatology; Barcelona Catalunya Spain
| | - X. Cubiró
- Hospital del Mar Medical Research Institute (IMIM); Universitat Autònoma Barcelona, (UAB) - Dermatology; Barcelona Catalunya Spain
| | - M. Bonfill-Ortí
- Hospital del Mar Medical Research Institute (IMIM); Universitat Autònoma Barcelona, (UAB) - Dermatology; Barcelona Catalunya Spain
| | - J. Garcias-Ladaria
- Hospital del Mar Medical Research Institute (IMIM); Universitat Autònoma Barcelona, (UAB) - Dermatology; Barcelona Catalunya Spain
| | - M. Villar
- Hospital del Mar Medical Research Institute (IMIM); Universitat Autònoma Barcelona, (UAB) - Dermatology; Barcelona Catalunya Spain
| | - X. García-Navarro
- Hospital del Mar Medical Research Institute (IMIM); Universitat Autònoma Barcelona, (UAB) - Dermatology; Barcelona Catalunya Spain
| | - I. Bielsa-Marsol
- Hospital del Mar Medical Research Institute (IMIM); Universitat Autònoma Barcelona, (UAB) - Dermatology; Barcelona Catalunya Spain
| | - M. Vilavella
- Hospital del Mar Medical Research Institute (IMIM); Universitat Autònoma Barcelona, (UAB) - Dermatology; Barcelona Catalunya Spain
| | - G. Aparicio
- Hospital del Mar Medical Research Institute (IMIM); Universitat Autònoma Barcelona, (UAB) - Dermatology; Barcelona Catalunya Spain
| | - C. Baliu-Piqué
- Hospital del Mar Medical Research Institute (IMIM); Universitat Autònoma Barcelona, (UAB) - Dermatology; Barcelona Catalunya Spain
| | - A. Álvarez
- Hospital del Mar Medical Research Institute (IMIM); Universitat Autònoma Barcelona, (UAB) - Dermatology; Barcelona Catalunya Spain
| | - N. Lamas-Domenech
- Hospital del Mar Medical Research Institute (IMIM); Universitat Autònoma Barcelona, (UAB) - Dermatology; Barcelona Catalunya Spain
| | - X. Duran-Jordà
- Hospital del Mar Medical Research Institute (IMIM); Universitat Autònoma Barcelona, (UAB) - Dermatology; Barcelona Catalunya Spain
| | - E. Serra-Baldrich
- Hospital del Mar Medical Research Institute (IMIM); Universitat Autònoma Barcelona, (UAB) - Dermatology; Barcelona Catalunya Spain
| | - A. Giménez-Arnau
- Hospital del Mar Medical Research Institute (IMIM); Universitat Autònoma Barcelona, (UAB) - Dermatology; Barcelona Catalunya Spain
| |
Collapse
|
13
|
Spertino J, Lopez-Ferrer A, Vilarrasa E, Puig L. Long-term study of infliximab for psoriasis in daily practice: drug survival depends on combined treatment, obesity and infusion reactions. J Eur Acad Dermatol Venereol 2015; 28:1514-21. [PMID: 25493314 DOI: 10.1111/jdv.12331] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
BACKGROUND Infiximab has been shown to be highly effective in phase III clinical trials, but limited information is available regarding drug survival and maintenance of efficacy beyond 1 year in real-life clinical setting. OBJECTIVES To analyse the efficacy and safety of infliximab in a large number of patients with a long follow-up and to identify clinical factors associated with long-term drug survival. METHODS A retrospective review of patients with moderate-to-severe psoriasis treated with infliximab from March 2004 to August 2012 at a tertiary dermatology centre was carried out. RESULTS In total, 63 treatment courses with infliximab were administered to 56 patients. The mean duration of treatment was 31.6 months. The only significant positive predictor of drug survival was combination treatment [hazard ratio (HR) vs. monotherapy 2.90, 95% confidence interval (CI) 1.42–5.92]. Significant negative predictors of drug survival were obesity (HR 0.40, 95% CI 0.19–0.87) and infusion reactions (HR 0.40, 95% CI 0.19–0.87). Infusion reactions occurred in 13 (23%) of our patients and were a reason for discontinuation of treatment in 5. CONCLUSIONS This retrospective review of a cohort of patients with moderate-to-severe psoriasis treated with infliximab in daily practice shows that the PASI75 response rates at 24 and 52 weeks of treatment are similar to those of the pivotal studies, but 37 courses of treatment (59%) had to be discontinued after a median of 12 months. The major cause for discontinuation was loss of response, in 18 cases. Combination treatment, obesity and infusion reactions were found to be predictors of drug survival.
Collapse
|